These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18935781)

  • 1. HIV drug resistance tendencies in Latvia.
    Kolupajeva T; Aldins P; Guseva L; Dusacka D; Sondore V; Viksna L; Rozentale B
    Cent Eur J Public Health; 2008 Sep; 16(3):138-40. PubMed ID: 18935781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Investigation of HIV-1 primary drug resistance mutations in antiretroviral therapy-naive cases].
    Yalçınkaya T; Köse S
    Mikrobiyol Bul; 2014 Oct; 48(4):585-95. PubMed ID: 25492654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States.
    Ross LL; Shortino D; Shaefer MS
    AIDS Res Hum Retroviruses; 2018 Aug; 34(8):672-679. PubMed ID: 29732898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria.
    Santoro MM; Ciccozzi M; Alteri C; Montieri S; Alexiev I; Dimova I; Ceccherini-Silberstein F; Beshkov D; Rezza G; Perno CF
    AIDS Res Hum Retroviruses; 2008 Sep; 24(9):1133-8. PubMed ID: 18788909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevalence of resistance to antiretroviral drugs in Spain].
    Larrú Martínez B; de José MI; Bellón JM; Gurbindo MD; León JA; Ciria L; Ramos JT; Mellado MJ; Pocheville I; Jiménez JL; Muñoz-Fernández M
    An Pediatr (Barc); 2007 Aug; 67(2):104-8. PubMed ID: 17692254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany.
    Oette M; Kaiser R; Däumer M; Akbari D; Fätkenheuer G; Rockstroh JK; Stechel J; Rieke A; Mauss S; Schmalöer D; Göbels K; Vogt C; Wettstein M; Häussinger D
    Eur J Med Res; 2004 May; 9(5):273-8. PubMed ID: 15257882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.
    Salomon H; Wainberg MA; Brenner B; Quan Y; Rouleau D; Coté P; LeBlanc R; Lefebvre E; Spira B; Tsoukas C; Sekaly RP; Conway B; Mayers D; Routy JP
    AIDS; 2000 Jan; 14(2):F17-23. PubMed ID: 10708278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the Northeast Region of Brazil.
    Cavalcanti AM; Lacerda HR; Brito AM; Pereira S; Medeiros D; Oliveira S
    Mem Inst Oswaldo Cruz; 2007 Nov; 102(7):785-92. PubMed ID: 17992369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and diversity of human immunodeficiency virus type 1 mutations associated with antiretroviral resistance among patients from Southern Brazil failing highly active antiretroviral therapy (HAART).
    Figueiredo Saad F; Kaminami Morimoto H; Wiechmann SL; Bonametti AM; Ueda LT; Matsuo T; Reiche EM
    Int J Mol Med; 2010 Oct; 26(4):585-93. PubMed ID: 20818500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The prevalence of primary HIV-1 drug resistance in newly reported HIV infections in Henan].
    Liu J; Xu W; He C; Yan J; Xing H; Xue XJ; Sun DY; Zhu Q; Wang Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 May; 37(5):643-7. PubMed ID: 27188354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on genotypic resistance mutations to antiretroviral drugs on HIV strains of treated and treatment-naive HIV-1 infectious patients in Hubei province].
    Wang XQ; Tong X; Tang H; Liu PP; Zhang W; Yang RG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Nov; 28(11):1112-5. PubMed ID: 18396668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naïve and first-line treatment failures in Djiboutian patients.
    Elmi Abar A; Jlizi A; Darar HY; Kacem MA; Slim A
    Diagn Pathol; 2012 Oct; 7():138. PubMed ID: 23044036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 subtypes in Luxembourg, 1983-2000.
    Deroo S; Robert I; Fontaine E; Lambert C; Plesséria JM; Arendt V; Staub T; Hemmer R; Schneider F; Schmit JC
    AIDS; 2002 Dec; 16(18):2461-7. PubMed ID: 12461421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.
    Mendoza Y; Castillo Mewa J; Martínez AA; Zaldívar Y; Sosa N; Arteaga G; Armién B; Bautista CT; García-Morales C; Tapia-Trejo D; Ávila-Ríos S; Reyes-Terán G; Bello G; Pascale JM
    PLoS One; 2016; 11(4):e0154317. PubMed ID: 27119150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diversity and prevalence of antiretroviral genotypic resistance mutations among HIV-1-infected children.
    Almeida FJ; Berezin EN; Rodrigues R; Sáfadi MA; Arnoni MV; Oliveira C; Brígido LF
    J Pediatr (Rio J); 2009; 85(2):104-9. PubMed ID: 19319446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone.
    Yendewa GA; Sahr F; Lakoh S; Ruiz M; Patiño L; Tabernilla A; Deen GF; Sesay M; Salata RA; Poveda E
    J Antimicrob Chemother; 2019 Jul; 74(7):2024-2029. PubMed ID: 30989237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
    Bunupuradah T; Suntarattiwong P; Li A; Sirivichayakul S; Pancharoen C; Boonrak P; Puthanakit T; Kerr SJ; Ruxrungtham K; Chotpitayasunondh T; Hirschel B; Ananworanich J;
    Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.